Page 13 - FLIPBOOK

Role of Abiraterone Acetate + Prednisolone +

ADT in High and Low Risk Metastatic Hormone
Addition of docetaxel to hormonal therapy in low and high

Naïve Prostate Cancer
Progress report – Docetaxel and
burden metastatic hormone sensitive prostate cancer:
long term survival results from the STAMPEDE trial
Mr Alex Hoyle MBChB MRCS
Presenter: Professor Nick James burden analysis
Abiraterone disease
(Christie GenitoUrinary Research Group Fellow, UK)

Noel W. Clarke, Adnan Ali, Fiona Ingleby, Alex Hoyle, Claire Amos, Gerhardt Attard, Simon Chowdhury, David Dearnaley,
Adnan Ali, Nick James, Chris Parker, Adrian Cook, Gert Attard, Simon Chowdhury, Bill Cross,
Hassan Douis, Silke Gillessen, Rob Jones, Zafar Malik, Malcolm Mason, Robin Millman, Chris Parker, Hannah Rush, Aurelius
David Dearnaley, Johann de Bono, Clare Gilson, Silke Gillessen, Rob Jones, David Matheson,
Omlin, Matthew Sydes, Mahesh Parmar, Nick James
Malcolm Mason, Alastair Ritchie, Martin Russell, Max Parmar, Matt Sydes, Noel Clarke;
on behalf of the STAMPEDE trial
for the STAMPEDE trial

Hoyle A, Clarke NW esmo.org
Medical Research Council - University Central

London

Christie NHS Foundation trust
Clarke NW, et al. Ann Oncol. 2019;30(12):1992–2003.

5/12/17

Progress report – Docetaxel and

Abiraterone disease burden analysis

Hoyle A, Clarke NW

Medical Research Council - University Central

London

Christie NHS Foundation trust

5/12/17